Evidence map›Paper›PMID 15804285›Full record

ArticleImmunology2005

Transforming growth factor-beta1 enhances the interferon-gamma-dependent, interleukin-12-independent pathway of T helper 1 cell differentiation.

Ronald B Smeltz, June Chen, Ethan M Shevach

Open access · greenAbstract read
In one paragraph

Article in Immunology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Lobomycosis: epidemiology, clinical presentation, and management options.Therapeutics and clinical risk management · 2014
    Review
  4. TGF-β activation and function in immunity.Annual review of immunology · 2014
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Ronald B SmeltzLaboratory of Immunology, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
June Chen
Ethan M Shevach
Howard Hughes Medical Institute · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · US

Funding

Control of Autoimmunity by Regulatory T CellsZIAAI000224 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SHEVACH, ETHAN · 2009 to 2025
$13.4M
RECEPTORS, CORECEPTORS, AND COUNTER RECEPTORS IN T CELL ACTIVATIONZ01AI000224 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI SHEVACH, ETHAN M. · 1985 to 2008
$3.5M
6 · The paper itself

Abstract

Transforming growth factor (TGF)-beta, a pleiotropic cytokine that has multiple effects on immune responses, has been shown to inhibit interleukin (IL)-4/GATA-3 expression as well as T helper 2 (Th2) differentiation. Consistent with these reports, we found that priming T cells from DO11.10 transgenic mice with antigen in the presence of TGF-beta inhibited GATA-3 expression and the development of IL-4-producing T cells. Unexpectedly, the inhibition of Th2 development was accompanied by a substantial increase in the number of interferon-gamma (IFN-gamma)-producing cells. T cells primed with TGF-beta secreted IFN-gamma in response to both T-cell receptor ligation and IL-12/IL-18 stimulation, and expressed high levels of T-bet and low levels of GATA-3. The TGF-beta-mediated enhancement of T helper 1 (Th1) priming was independent of IL-12 and signal transducer and activator of transcription (STAT)-4, but required endogenous IFN-gamma. TGF-beta-mediated enhancement of the IFN-gamma-dependent, IL-12-independent pathway of Th1 priming was mediated primarily by the inhibition of IL-4 produced by memory/activated T cells in the unfractionated CD4+ responder population. Nevertheless, TGF-beta did not inhibit this pathway of Th1 differentiation when purified naive CD4+ T cells were used as responders. These data have important implications for strategies being considered for the use of TGF-beta-producing T cells for the treatment of autoimmune disorders.

Indexed as

AnimalsCell DifferentiationCytokinesDNA-Binding ProteinsFemaleGATA3 Transcription FactorImmunologic MemoryInterferon-gammaInterleukin-12Interleukin-4MiceMice, Inbred C57BLMice, TransgenicSTAT4 Transcription FactorT-bet Transcription FactorT-Box Domain ProteinsCytokinesDNA-Binding ProteinsGata3 protein, mouseGATA3 Transcription FactorInterferon-gammaInterleukin-12Interleukin-4Stat4 protein, mouseSTAT4 Transcription FactorT-bet Transcription FactorT-Box Domain ProteinsTrans-ActivatorsTranscription FactorsTransforming Growth Factor beta

Identifiers

PMID15804285
PMCPMC1782105
OpenAlexW2032524525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.